ACAD earnings date and last-quarter result: last quarter beat, P/E 11.19. Updated 2026-07-23.
ACADIA Pharmaceuticals (ACAD) Research Hub
ACADIA Pharmaceuticals (ACAD) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 19.74 USD (+0.05%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 11.19, market cap 4.28B. This hub links to the full technical, earnings and options research available for ACAD.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 19.74 USD (+0.05%) |
| 52-week range | 18.39 USD – 30.96 USD |
| Trend regime | Range |
| 14-day RSI | 50 (Neutral) |
| Trailing P/E | 11.19 |
| Market cap | 4.28B |
| Dividend yield | 0.00% |
Available research for ACAD
Covered Call on ACAD: how it works, illustrative setup around the real 19.74 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACAD: how it works, illustrative setup around the real 19.74 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACAD: how it works, illustrative setup around the real 19.74 USD price, max profit/loss, breakeven and when to use it. Educational.
ACAD technical analysis: range, last 19.74 USD, RSI 50, 52w range 18.39 USD–30.96 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ACAD in?
ACADIA Pharmaceuticals (ACAD) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACAD in an uptrend or downtrend?
As of 2026-10-26, ACAD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACAD's trailing P/E ratio?
ACAD's trailing P/E is 11.19, with a market cap of 4.28B. See the earnings research page for full valuation detail.